It is very uncertain whether oral iron changes serious adverse events compared with inactive control (very low certainty).
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).
Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
Oral contraceptive pill (OCP) may leads to lower adverse events ‐ Minor compared with metformin combined with OCP (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).
Oral contraceptive pill (OCP) may leads to lower adverse events ‐ Severe compared with metformin combined with OCP (low certainty).
It is very uncertain whether oral contraceptive pill (OCP) changes adverse events ‐ Severe compared with metformin combined with OCP (very low certainty).
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
Partial oral treatment showed no clear difference in adverse events compared with conventional intravenous treatment of endocarditis on the left side… (low certainty).
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
The review found no eligible studies for this question.
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: new‐onset glucose intolerance compared with oral steroids alone (low certainty).